Back to search

Article

First-line pembrolizumab, trastuzumab, and chemotherapy in advanced HER2-positive gastric cancer with sequential genomic profiling

2021-02-23

Abstract excerpt

<title>Abstract</title> <p>Combining programmed cell death 1 (PD-1) and human epidermal receptor 2 (HER2) targeting agents has shown synergy in HER2-positive preclinical cancer models. Here, we describe a single-arm multi-institutional phase Ib/II trial combining pembrolizumab, trastuzumab, and chemotherapy (capecitabine plus cisplatin) as first-line therapy for HER2-positive advanced gastric cancer (AGC). With a...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
a93f3546-8ac2-5dad-9fe1-46a7ce2d5212
DOI
10.21203/rs.3.rs-254208/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
First-line pembrolizumab, trastuzumab, and chemotherapy in advanced HER2-positive gastric cancer with sequential genomic profilingDOI 10.21203/rs.3.rs-254208/v1
The genomics and therapeutics of HER2-positive gastric cancer—from trastuzumab and beyondSemantic proximity
HER2 Amplification and PD-L1 Expression in Advanced Gastric Cancer: Correlations, Clinical Implications, and Molecular CharacteristicsSemantic proximity
Genomic correlations for clinical outcomes in HER2-positive advanced gastric cancers treated using trastuzumab-based therapySemantic proximity
Molecular evolutionary process of advanced gastric cancer during sequential chemotherapy detected by circulating tumor DNA.Semantic proximity
Sequential pembrolizumab cooperates with platinum/5FU to remodel the tumor immune microenvironment in advanced gastric cancer: A phase II chemoimmunotherapy trialSemantic proximity
Circulating tumor DNA predicts clinical benefits of immune checkpoint blockade in HER2-negative patients with advanced gastric cancerSemantic proximity
Exploring potential molecular resistance and clonal evolution in advanced HER2-positive gastric cancer under trastuzumab therapySemantic proximity
Prospective comprehensive genomic profiling of advanced gastric carcinoma cases reveals frequent clinically relevant genomic alterations and new routes for targeted therapies.Semantic proximity
Trastuzumab in combination with capecitabine plus cisplatin for the treatment of advanced HER2-positive gastric cancer: A systematic review and meta-analysisSemantic proximity
Genomic Profiling of HER2-Positive Gastric Cancer: PI3K/Akt/mTOR Pathway as Predictor of Outcomes in HER2-Positive Advanced Gastric Cancer Treated with TrastuzumabSemantic proximity
Whole Genome Sequencing in single CTC improves clinical outcome in Her-2 negative breast cancer patientsSemantic proximity
The impact of concomitant genomic alterations on treatment outcome for trastuzumab therapy in HER2-positive gastric cancer.Semantic proximity
Select a neighboring publication to make it the new centre.